4506 — Sumitomo Pharma Co Balance Sheet
0.000.00%
Last trade - 00:00
- ¥155bn
- ¥524bn
- ¥556bn
- 16
- 54
- 44
- 27
2019 March 31st | C2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 181,046 | 130,425 | 223,178 | 238,580 | 163,652 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 119,243 | 140,368 | 136,060 | 151,500 | 98,630 |
Total Inventory | |||||
Total Other Current Assets | |||||
Total Current Assets | 373,268 | 364,090 | 459,795 | 499,521 | 381,860 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 59,485 | 65,748 | 64,966 | 64,091 | 58,909 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 834,717 | 1,256,534 | 1,308,127 | 1,308,007 | 1,134,742 |
Accounts Payable | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 198,174 | 496,498 | 278,147 | 278,373 | 372,694 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 336,579 | 723,864 | 727,557 | 700,119 | 727,993 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 498,138 | 532,670 | 580,570 | 607,888 | 406,749 |
Total Liabilities & Shareholders' Equity | 834,717 | 1,256,534 | 1,308,127 | 1,308,007 | 1,134,742 |
Total Common Shares Outstanding |